NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
NVS - Novartis AG
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$146.00
DETAILS
HIGH:
$156.00
LOW:
$136.00
MEDIAN:
$146.00
CONSENSUS:
$146.00
DOWNSIDE:
5.16%
Stock News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
US FDA expands use of Novartis drug for chronic skin condition
The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, the Swiss drugmaker said on Wednesday.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors
On September 29, 2026, Novartis AG (NVS) shares fell 0.8% today, trading at $145.71. The stock has fluctuated between a 52-week high of $170.46 and a low of $12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE: NVS). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Novartis stock on August 27th. The trade occurred in the Representative's "KEVIN HERN TRADITIONAL IRA" account. Representative Kevin Hern also recently made the following trade(s):
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Novartis and Redhill Biopharma's net
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
Price Targets
Novartis price target lowered to $156 from $170 at Morgan Stanley
$156.00
(was $140.85)
Thibault Boutherin
·
Morgan Stanley
HSBC upgrades Novartis to Hold with negative catalysts played out
$136.00
(was $137.48)
HSBC
Novartis price target raised to $170 from $143 at Morgan Stanley
$170.00
(was $149.70)
Thibault Boutherin
·
Morgan Stanley
Novartis price target raised to $112 from $106 at HSBC
$112.00
(was $131.01)
HSBC
Novartis price target raised to $143 from $136 at Morgan Stanley
$143.00
(was $132.28)
Morgan Stanley
Novartis (NVS) PT Raised to $126 at CFRA
$126.00
(was $123.33)
Wan Nurhayati
·
CFRA
Novartis (NVS) PT Raised to $120 at BMO Capital
$120.00
(was $109.91)
Etzer Darout
·
BMO Capital
Novartis downgraded to Neutral from Buy at Goldman Sachs
$121.00
(was $119.38)
James Quigley
·
Goldman Sachs
Novartis (NVS) PT Raised to $118 at BMO Capital
$118.00
(was $106.13)
Etzer Darout
·
BMO Capital
Novartis (NVS) PT Raised to $108 at CFRA
$108.00
(was $97.27)
Wan Nurhayati
·
CFRA